|
시장보고서
상품코드
2076221
섬망 상태 초조 관리 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 지역별Agitation in Delirium Management Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
섬망 상태 초조 관리 시장 규모는 2026년에 2억 7,170만 달러로 추정되고 있으며, 2033년까지 3억 7,730만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 4.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 2억 7,170만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 4.80% | 2033년 시장 규모 예측 : | 3억 7,730만 달러 |
섬망은 사람의 정신 기능에 장애를 일으키는 신경학적 상태입니다. 이로 인해 의식이 혼미해지거나 정서적 불안정이 발생합니다. 섬망은 노화, 특정 약물의 복용, 알코올 남용, 수술 및 기타 의료 처치 외에도 유독 물질이나 감염성 물질에 대한 노출, 신체적 외상, 식습관, 그 밖의 행동적·직업적 요인 등 다양한 원인에 의해 유발될 수 있습니다. 섬망에는 '과활동성 섬망"와 "저활동성 섬망'의 두 가지 유형이 있습니다. 과활동성 섬망에서는 환자가 지나치게 활동적이 됩니다(섬망에 수반되는 흥분 상태). 현재 시장 관계자들은 섬망으로 인한 환자의 흥분 상태를 관리하기 위한 신약 평가를 위한 연구개발 활동을 진행하고 있습니다.
시장 역학
연구 기관과 시장 관계자들은 중환자실(ICU)에 입원해 있는 중증 환자의 섬망에 따른 흥분 상태를 치료하는 약물의 안전성과 유효성을 검증하기 위한 연구개발 활동에 주력하고 있습니다. 예를 들어 2017년에 캘리포니아 대학교 샌디에이고 캠퍼스의 연구진은 수술 후 수면 부족이 중환자실(ICU) 환자에게 섬망(의식 혼탁)을 유발한다는 사실을 보고했습니다. 이에 연구진은 멜라토닌(신체의 일주기 리듬과 수면·각성 주기를 조절하는 호르몬)의 작용을 모방하는 약물인 라멜테온이 수면의 질을 개선하는 데 어떤 역할을 하는지 확인하기 위한 임상시험을 진행하고 있습니다. 수면의 질을 개선함으로써, 흉부 개흉술 후 환자의 섬망 발병을 예방하는 데 도움이 될 것으로 기대됩니다. 이 연구는 2021년 12월 1일까지 완료될 전망입니다.
시장 관련 기업은 섬망 치료를 목적으로 한 차세대 1세대 항정신병 약물의 출시에 주력하고 있으며, 이는 전 세계 섬망 상태 초조 관리 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2017년에는 루팡 리미티드가 미국 식품의약국(미국 FDA)의 승인을 받은 후, 푸마르산 퀘티아핀 서방정(50mg, 150mg, 200mg, 300mg, 400mg)을 출시했습니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 다음의 매개변수를 바탕으로 전 세계 섬망 상태 초조 관리 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 및 전략, 그리고 향후 계획입니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 섬망 상태 초조 관리 시장 보고서'는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 섬망 상태 초조 관리 시장을 분석하는 데 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 섬망 상태 초조 관리 시장
제5장 세계의 섬망 상태 초조 관리 시장 : 약제 유형별, 2021-2033년
제6장 세계의 섬망 상태 초조 관리 시장 : 투여 경로별, 2021-2033년
제7장 세계의 섬망 상태 초조 관리 시장 : 유통 채널별, 2021-2033년
제8장 세계의 섬망 상태 초조 관리 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.07.09Agitation In Delirium Management Market is estimated to be valued at USD 271.7 Mn in 2026 and is expected to reach USD 377.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 271.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.80% | 2033 Value Projection: | USD 377.3 Mn |
Delirium is a neurological condition which leads to disturbances in the mental abilities of a person. It causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as old age, exposure to certain medications, alcohol abuse, surgery or other medical procedures and factors such as exposure to toxic or infectious agents, physical trauma, diet, and other behavioral and occupational factors. There are two types of delirium: Hyperactive delirium and Hypoactive delirium. In hyperactive delirium, patients become overactive (agitation in delirium). Currently, market players are carrying out research and development activities for evaluating new medicines for the management of agitation in delirium among the patients.
Market Dynamics
Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients. For instance, in 2017, researchers at the University of California, San Diego, reported that sleep deprivation post-surgery causes delirium (confusion) in patients in the intensive care unit (ICU). Thus, they are conducting clinical trials for studying the role of Ramelteon, a medication that mimics the activity of melatonin (hormone which controls the body's circadian rhythm or sleep - wake cycle) in improving the sleep quality, thus improving sleep quality is expected to help in preventing occurrence of delirium in the patients post open-heart surgery. The study is expected to be completed by December 1, 2021.
Market players are indulged in launching new first-generation antipsychotic drugs for the treatment of delirium, which is expected to spur the growth of the global agitation in delirium management market. For instance, in 2017, Lupin Limited launched Quetiapine Fumarate Extended-Release Tablets (50 mg, 150 mg, 200 mg, 300 mg and 400 mg strengths), after receiving approval from the U.S. Food and Drug Administration (U.S. FDA).
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global agitation in delirium management market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis International AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., and BioXcel Therapeutics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the agitation in delirium management market
Detailed Segmentation:
- Global Agitation in Delirium Management Market, By Drug (Revenue, USD Mn, 2021 - 2033)
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- Global Agitation in Delirium Management Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Intramuscular
- Others
- Global Agitation in Delirium Management Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Agitation in Delirium Management Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- By Drug:
- Latin America
- By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug:
- Europe
- By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug:
- Asia Pacific
- By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug:
- Middle East
- By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug:
- Africa
- By Drug:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- Others
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug:
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Mylan N.V.
- Fresenius Kabi AG
- Novartis International AG
- Akorn Incorporated
- Zydus Cadila
- Pfizer, Inc.
- BioXcel Therapeutics, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Approvals/Launches
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Pricing Analysis
- Key Developments
- PEST Analysis
- Porter€(TM)s Analysis
4. Global Agitation in Delirium Management Market
- Economic Impact
- Impact on Supply and Demand
5. Global Agitation in Delirium Management Market, By Drug Type, 2021€" 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- First-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€" 2033, (US$ Mn)
- Segment Trends
- Second-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
- Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
6. Global Agitation in Delirium Management Market, By Route of Administration, 2021 €" 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
7. Global Agitation in Delirium Management Market, By Distribution Channel, 2021 €" 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
8. Global Agitation in Delirium Management Market, By Region, 2021 €" 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021€"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €"2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021€"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €"2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021€"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €"2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021€"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €"2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021€"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €"2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 €"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021€"2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €"2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fresenius Kabi AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Akorn Incorporated
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BioXcel Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Analysts€(TM) Views
10. Section
- References
- Research Methodology
- About us and Sales Contact
